Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) Research & Development (2019 - 2025)

Pulmonx (LUNG) has disclosed Research & Development for 7 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 29.43% to $4.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.9 million, a 8.27% increase, with the full-year FY2024 number at $17.6 million, down 2.82% from a year prior.
  • Research & Development was $4.8 million for Q3 2025 at Pulmonx, down from $5.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.7 million in Q2 2023 to a low of $2.8 million in Q3 2021.
  • A 5-year average of $4.2 million and a median of $4.0 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 145.86% in 2021, then decreased 11.28% in 2024.
  • Pulmonx's Research & Development stood at $3.7 million in 2021, then rose by 5.26% to $3.9 million in 2022, then dropped by 0.18% to $3.9 million in 2023, then rose by 2.7% to $4.0 million in 2024, then rose by 21.12% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Research & Development are $4.8 million (Q3 2025), $5.3 million (Q2 2025), and $4.8 million (Q1 2025).